Jpmorgan Chase & CO Viking Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,251,671 shares of VKTX stock, worth $164 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,251,671
Previous 1,040,158
116.47%
Holding current value
$164 Million
Previous $85.3 Million
39.94%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding VKTX
# of Institutions
462Shares Held
65.9MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$736 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$439 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$373 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$135 Million0.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.4MShares$102 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.59B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...